Assess Immunogenicity, Reactogenicity of GSK Biologicals'-dTpa-IPV Vaccine Versus dTpa and IPV Vaccines Administered Separately and Compared With Aventis Pasteur MSD's Td-IPV Vaccine When Administered to Healthy Adolescents and Adults.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DTaP poliovirus vaccine (Primary) ; DT-poliovirus vaccine; DTaP vaccine; Poliovirus vaccine inactivated
Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
Focus Pharmacodynamics; Registrational
Sponsors GlaxoSmithKline; GSK

Most Recent Events

No Data Available

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight